Inhaled vaccine delivery in the combat against respiratory viruses: a 2021 overview of recent developments and implications for COVID-19

References

• Li X, Mukandavire C, Cucunubá ZM, et al. Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study. Lancet. 2021;397(10272):398–408.
   PubMed Web of Science ®Google Scholar
• Saker L, Lee K, Cannito B, et al. Globalization and Infectious Diseases: a review of the Linkages. Spec Top Soc Econ Behav Res Geneva World Heal Organ; 2004.
   Google Scholar
• Brattig NW, Tanner M, Bergquist R, et al. Impact of environmental changes on infectious diseases: key findings from an international conference in Trieste, Italy in May 2017. Acta Trop. 2021;213:105165.
   PubMed Web of Science ®Google Scholar
• Weaver SC, Reisen WK. Present and future arboviral threats. Antiviral Res. 2010;85(2):328–345.
   PubMed Web of Science ®Google Scholar
• Giudice EL, Campbell JD. Needle-free vaccine delivery. Adv Drug Deliv Rev. 2006;58(1):68–89. Elsevier.
   PubMed Web of Science ®Google Scholar
• Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol. 2006;6(2):148–158.
   PubMed Web of Science ®Google Scholar
• Mitragotri S. Immunization without needles. Nat Rev Immunol. 2005;5(12):905–916.
   PubMed Web of Science ®Google Scholar
• Kersten G, Hirschberg H. Needle-free vaccine delivery. Expert Opin Drug Deliv. 2007 Taylor & Francis;4(5):459–474.
   PubMed Web of Science ®Google Scholar
• Cryan S-A, Sivadas N, Garciacontreras L. In vivo animal models for drug delivery across the lung mucosal barrier. Adv Drug Deliv Rev. 2007;59(11):1133–1151.
   PubMed Web of Science ®Google Scholar
• Kohlmeier JE, Woodland DL. Immunity to Respiratory Viruses. Annu Rev Immunol. 2009;27(1):61–82.
   PubMedGoogle Scholar
• De Bree GJ, Van Leeuwen EMM, Out TA, et al. Selective accumulation of differentiated CD8+ T cells specific for respiratory viruses in the human lung. J Exp Med. 2005;202(10):1433–1442.
   PubMed Web of Science ®Google Scholar
• Hogan RJ, Usherwood EJ, Zhong W, et al. Activated Antigen-Specific CD8 + T Cells Persist in the Lungs Following Recovery from Respiratory Virus Infections. J Immunol. 2001;166(3):1813–1822.
   PubMed Web of Science ®Google Scholar
• Waldman RH, Mann JJ, Small PA. Immunization Against Influenza: Prevention of Illness in Man by Aerosolized Inactivated Vaccine. JAMA J Am Med Assoc. 1969;207:520–524.
   PubMed Web of Science ®Google Scholar
• Waldman RH, Bond JO, Levitt LP, et al. An evaluation of influenza immunization: influence of route of administration and vaccine strain. Bull World Health Organ. 1969;41(3):543–548.
   PubMed Web of Science ®Google Scholar
• Waldman RH, Wood SH, Torres EJ, et al. Influenza antibody response following aerosal administration of inactivated viruis. Am J Epidemiol. 1970;91(6):575–584.
   Web of Science ®Google Scholar
• Waldman RH, Coggins WJ. Influenza Immunization: field Trial on a University Campus. J Infect Dis. 1972;126(3):242–248.
   PubMed Web of Science ®Google Scholar
• Haigh W, Howell RW. The Efficacy of the A2/Aichi/68 Strain in Inhaled Influenza Immunisation Against the A/England/42/72 Variant. Occup Med (Chic Ill). 1973;23(4):125–127.
   Google Scholar
• Haigh W, Howell RW, Meichen FW. A comparative trial of influenza immunization by inhalation and hypojet methods. Practitioner. 1973;211(263):365–370.
   PubMedGoogle Scholar
• Kress S, Schluederberg AE, Hornick RB, et al. Studies with live attenuated measles-virus vaccine: II. clinical and immunologic response of children in an open community. Am J Dis Child. 1961;101:701–707.
   PubMedGoogle Scholar
• McCrumb FR, Kress S, Saunders E, et al. Studies with live attenuated measles-virus vaccine: i. clinical and immunologic responses in Institutionalized Children. Am J Dis Child. 1961;101:689–700.
   Google Scholar
• Dilraj A, Cutts FT, Fernandez De Castro J, et al. Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial. Lancet. 2000;355(9206):798–803.
   PubMed Web of Science ®Google Scholar
• Bennett JV, De Castro JF, Valdespino-Gomez JL, et al. Aerosolized measles and measles-rubella vaccines induce better measles antibody booster responses than injected vaccines: randomized trials in Mexican schoolchildren. Bull World Health Organ. 2002;80(10):806–812.
   PubMed Web of Science ®Google Scholar
• Fernández-de Castro J, Kumate-Rodríguez J, Sepúlveda J, et al. [Measles vaccination by the aerosol method in Mexico]. Salud Publica Mex. 1997;39(1):53–60.
   PubMed Web of Science ®Google Scholar
• Satti I, Meyer J, Harris SA, et al. Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial. Lancet Infect Dis. 2014;14(10):939–946.
   PubMed Web of Science ®Google Scholar
• Manjaly Thomas Z-R, Satti I, Marshall JL, et al. Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: a phase I randomised controlled trial. PLOS Med. 2019;16:e1002790.
   PubMed Web of Science ®Google Scholar
• Lloyd CM, Marsland BJ. Lung Homeostasis: influence of Age, Microbes, and the Immune System. Immunity. 2017;46(4):549–561.
   PubMed Web of Science ®Google Scholar
• Pilette C, Ouadrhiri Y, Godding V, et al. Lung mucosal immunity: immunoglobulin-A revisited. Eur Respir J. 2001;18(3):571–588.
   PubMed Web of Science ®Google Scholar
• Randall TD. Structure, organization, and development of the mucosal immune system of the respiratory tract. Mucosal Immunol. 2015; Elsevier.43–61.
   Google Scholar
• Randall TD. Bronchus-associated lymphoid tissue (BALT) structure and function. Adv Immunol. 2010;107:187–241.
   PubMed Web of Science ®Google Scholar
• Silva-Sanchez A, Randall TD. Role of iBALT in Respiratory Immunity. Curr Top Microbiol Immunol. 2020;21–43. Springer Science and Business Media Deutschland GmbH
   PubMed Web of Science ®Google Scholar
• Moyron-Quiroz JE, Rangel-Moreno J, Hartson L, et al. Persistence and responsiveness of immunologic memory in the absence of secondary lymphoid organs. Immunity. 2006;25(4):643–654.
   PubMed Web of Science ®Google Scholar
• GeurtsvanKessel CH, Willart MAM, Bergen IM, et al. Dendritic cells are crucial for maintenance of tertiary lymphoid structures in the lung of influenza virus-infected mice. J Exp Med. 2009;206(11):2339–2349.
   PubMed Web of Science ®Google Scholar
• Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med. 2005;11(S4):S45–S53.
   PubMed Web of Science ®Google Scholar
• Lo DD. Vigilance or subversion? constitutive and inducible M cells in mucosal tissues. Trends Immunol. 2018;39(3):185–195.
   PubMed Web of Science ®Google Scholar
• Pilette C, Ouadrhiri Y, Godding V, et al. Lung mucosal immunity: immunoglobulin-A revisited. Eur Respir J. 2001;18(3):571–588.
   PubMed Web of Science ®Google Scholar
• Bhaskar S, Sinha A, Banach M, et al. Cytokine storm in COVID-19—immunopathological mechanisms, clinical considerations, and therapeutic approaches: the REPROGRAM consortium position paper. Front Immunol. 2020;11:1648.
   PubMed Web of Science ®Google Scholar
• Pearce L, Davidson SM, Yellon DM. The cytokine storm of COVID-19: a spotlight on prevention and protection. Expert Opin Ther Targets. 2020;24(8):723–730.
   PubMed Web of Science ®Google Scholar
• Salvi S, Holgate ST. Could the airway epithelium play an important role in mucosal immunoglobulin A production? Clin Exp Allergy. 199929(12):1597–1605.
   PubMed Web of Science ®Google Scholar
• Chiu C, Openshaw PJ. Antiviral B cell and T cell immunity in the lungs. Nat Immunol. 2015;16(1):18–26.
   PubMed Web of Science ®Google Scholar
• Kato A, Hulse KE, Tan BK, et al. B-lymphocyte lineage cells and the respiratory system. J Allergy Clin Immunol. 2013;131(4):933–957.
   PubMed Web of Science ®Google Scholar
• Johansen F-E, Kaetzel CS. Regulation of the polymeric immunoglobulin receptor and IgA transport: new advances in environmental factors that stimulate pIgR expression and its role in mucosal immunity. Mucosal Immunol. 2011;4(6):598–602.
   PubMed Web of Science ®Google Scholar
• Woof JM, Kerr MA. The function of immunoglobulin A in immunity. J Pathol. 2006;208(2):270–282.
   PubMed Web of Science ®Google Scholar
• Mantis NJ, Forbes SJ. Secretory IgA: arresting microbial pathogens at epithelial borders. Immunol Invest. 2010;39(4–5):383–406.
   PubMed Web of Science ®Google Scholar
• Brandtzaeg P. Function of mucosa-associated lymphoid tissue in antibody formation. Immunol Invest. 2010;39(4–5):303–355.
   PubMed Web of Science ®Google Scholar
• Brandtzaeg P, Farstad IN, Haraldsen G. Regional specialization in the mucosal immune system: primed cells do not always home along the same track. Immunol Today. 2015;16(6):267–277.
   Google Scholar
• Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med. 2005;11(S4):S45–S53.
   PubMed Web of Science ®Google Scholar
• Tonnis WF, Lexmond AJ, Frijlink HW, et al. Devices and formulations for pulmonary vaccination. Expert Opin Drug Deliv. 2013;10(10):1383–1397.
   PubMed Web of Science ®Google Scholar
• Friebel C, Steckel H. Single-use disposable dry powder inhalers for pulmonary drug delivery. Expert Opin Drug Deliv. 2010;7(12):1359–1372.
   PubMed Web of Science ®Google Scholar
• De Boer AH, Hagedoorn P. The role of disposable inhalers in pulmonary drug delivery. Expert Opin Drug Deliv. 2015;12(1):143–157.
   PubMed Web of Science ®Google Scholar
• Sibum I, Hagedoorn P, De Boer AH, et al. Challenges for pulmonary delivery of high powder doses. Int J Pharm. 2018;548(1):325–336.
   PubMedGoogle Scholar
• Pharmaceutical Particle VR. Engineering via Spray Drying. Pharm Res. 2008;25:999–1022.
   PubMed Web of Science ®Google Scholar
• Mensink MA, Frijlink HW, Van Der Voort Maarschalk K, et al. How sugars protect proteins in the solid state and during drying (review): mechanisms of stabilization in relation to stress conditions. Eur J Pharm Biopharm. 2017;114:288–295.
   PubMed Web of Science ®Google Scholar
• Amorij JP, Huckriede A, Wilschut J, et al. Development of stable influenza vaccine powder formulations: challenges and possibilities. Pharm Res. 2008;25(6):1256–1273.
   PubMed Web of Science ®Google Scholar
• Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6(1):67–74.
   PubMed Web of Science ®Google Scholar
• Heyder J. Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery. Proc Am Thorac Soc. 2004;1(4):315–320.
   PubMedGoogle Scholar
• Bhide Y, Tomar J, Dong W, et al. Pulmonary delivery of influenza vaccine formulations in cotton rats: site of deposition plays a minor role in the protective efficacy against clinical isolate of H1N1pdm virus. Drug Deliv. 2018;25(1):533–545.
   PubMed Web of Science ®Google Scholar
• Tomar J, Tonnis WF, Patil HP, et al. Pulmonary immunization: deposition site is of minor relevance for influenza vaccination but deep lung deposition is crucial for hepatitis B vaccination. Acta Pharm Sin B. 2019;9(6):1231–1240.
   PubMed Web of Science ®Google Scholar
• Minne A, Louahed J, Mehauden S, et al. The delivery site of a monovalent influenza vaccine within the respiratory tract impacts on the immune response. Immunology. 2007;122(3):316–325.
   PubMed Web of Science ®Google Scholar
• Benne N, Van Duijn J, Kuiper J, et al. Orchestrating immune responses: how size, shape and rigidity affect the immunogenicity of particulate vaccines. J Control Release. 2016;234:124–134.
   PubMed Web of Science ®Google Scholar
• Hellfritzsch M, Scherließ R. Mucosal vaccination via the respiratory tract. Pharmaceutics. 2019;11(8):375.
   PubMed Web of Science ®Google Scholar
• Lycke N. Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol. 2012;12(8):592–605.
   PubMed Web of Science ®Google Scholar
• Patil HP, Murugappan S, De Vries-idema J, et al. Comparison of adjuvants for a spray freeze-dried whole inactivated virus influenza vaccine for pulmonary administration. Eur J Pharm Biopharm. 2015;93:231–241.
   PubMed Web of Science ®Google Scholar
• Amorij J-P, Saluja V, Petersen AH, et al. Pulmonary delivery of an inulin-stabilized influenza subunit vaccine prepared by spray-freeze drying induces systemic, mucosal humoral as well as cell-mediated immune responses in BALB/c mice. Vaccine. 2007;25(52):8707–8717.
   PubMed Web of Science ®Google Scholar
• Nardellihaefliger D, Lurati F, Wirthner D, et al. Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine. Vaccine. 2005;23(28):3634–3641.
   PubMed Web of Science ®Google Scholar
• Low N, Kraemer S, Schneider M, et al. Immunogenicity and safety of aerosolized measles vaccine: systematic review and meta-analysis. Vaccine. 2008;26(3):383–398.
   PubMed Web of Science ®Google Scholar
• Hiremath GS, Omer SB. A meta-analysis of studies comparing the respiratory route with the subcutaneous route of measles vaccine administration. Hum Vaccin. 2012;12(1):30–36.
   Google Scholar
• Low N, Bavdekar A, Jeyaseelan L, et al. A randomized, controlled trial of an aerosolized vaccine against measles. N Engl J Med. 2015;372(16):1519–1529.
   PubMed Web of Science ®Google Scholar
• Wong-Chew RM, García-León ML, Torrija BET, et al. Increasing the time of exposure to aerosol measles vaccine elicits an immune response equivalent to that seen in 9-month-old Mexican children given the same dose subcutaneously. J Infect Dis. 2011;204(3):426–432.
   PubMed Web of Science ®Google Scholar
• Agarkhedkar S, Kulkarni PS, Winston S, et al. Safety and immunogenicity of dry powder measles vaccine administered by inhalation: a randomized controlled Phase I clinical trial. Vaccine. 2014;32(50):6791–6797.
   PubMed Web of Science ®Google Scholar
• Cape SP, Villa JA, Huang ETS, et al. Preparation of active proteins, vaccines and pharmaceuticals as fine powders using supercritical or near-critical fluids. Pharm Res. 2008;25(9):1967–1990.
   PubMed Web of Science ®Google Scholar
• Lin W-H, Griffin DE, Rota PA, et al. Successful respiratory immunization with dry powder live-attenuated measles virus vaccine in rhesus macaques. Proc Natl Acad Sci. 2011;108(7):2987–2992.
   PubMed Web of Science ®Google Scholar
• Dilraj A, Sukhoo R, Cutts FT, et al. Aerosol and subcutaneous measles vaccine: measles antibody responses 6 years after re-vaccination. Vaccine. 2007;25(21):4170–4174.
   PubMed Web of Science ®Google Scholar
• Patil HP, Murugappan S, Ter Veer W, et al. Evaluation of monophosphoryl lipid A as adjuvant for pulmonary delivered influenza vaccine. J Control Release. 2014;174:51–62.
   PubMed Web of Science ®Google Scholar
• Audouy SAL, Van Der Schaaf G, Hinrichs WLJ, et al. Development of a dried influenza whole inactivated virus vaccine for pulmonary immunization. Vaccine. 2011;29(26):4345–4352.
   PubMed Web of Science ®Google Scholar
• Saluja V, Amorij J-P, Kapteyn JC, et al. A comparison between spray drying and spray freeze drying to produce an influenza subunit vaccine powder for inhalation. J Control Release. 2010;144(2):127–133.
   PubMed Web of Science ®Google Scholar
• Smith DJ, Bot S, Dellamary L, et al. Evaluation of novel aerosol formulations designed for mucosal vaccination against influenza virus. Vaccine. 2003;21(21–22):2805–2812.
   PubMed Web of Science ®Google Scholar
• Kisich KO, Higgins MP, Park I, et al. Dry powder measles vaccine: particle deposition, virus replication, and immune response in cotton rats following inhalation. Vaccine. 2011;29(5):905–912.
   PubMed Web of Science ®Google Scholar
• De Swart RL, LiCalsi C, Quirk AV, et al. Measles vaccination of macaques by dry powder inhalation. Vaccine. 2007;25(7):1183–1190.
   PubMed Web of Science ®Google Scholar
• Muttil P, Prego C, Garcia-Contreras L, et al. Immunization of guinea pigs with novel hepatitis b antigen as nanoparticle aggregate powders administered by the pulmonary route. Aaps J. 2010;12(3):330–337.
   PubMed Web of Science ®Google Scholar
• Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586(7830):516–527.
   PubMed Web of Science ®Google Scholar
• Dong Y, Dai T, Wei Y, et al. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct Target Ther. 2020;5(1):237.
   PubMed Web of Science ®Google Scholar
• Takes Key FDA Action in fight against COVID-19 by issuing emergency use authorization for first COVID-19 vaccine | federal drug administration [ Internet]. 2020 [ cited 2021 Jan 13]. Available from: https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19.
   Google Scholar
• FDA Takes additional action in fight against COVID-19 by issuing emergency use authorization for second COVID-19 vaccine | federal drug administration [ Internet]. [ cited 2021 Jan 13]. Available from: https://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-covid.
   Google Scholar
• EMA recommends COVID-19 Vaccine Moderna for authorisation in the EU | european Medicines Agency [ Internet]. [ cited 2021 Jan 13]. Available from: https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-moderna-authorisation-eu.
   Google Scholar
• EMA recommends first COVID-19 vaccine for authorisation in the EU | european Medicines Agency [ Internet]. [ cited 2021 Jan 13]. Available from: https://www.ema.europa.eu/en/news/ema-recommends-first-covid-19-vaccine-authorisation-eu.
   Google Scholar
• COVID-19 Vaccine U.S. Distribution Fact Sheet | pfizer [ Internet]. [ cited 2020 Dec 15]. Available from: https://www.pfizer.com/news/hot-topics/covid_19_vaccine_u_s_distribution_fact_sheet.
   Google Scholar
• Moderna Announces Longer Shelf Life for its COVID-19 Vaccine Candidate at Refrigerated Temperatures | moderna, Inc. [ Internet]. [ cited 2020 Dec 15]. Available from: https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-longer-shelf-life-its-covid-19-vaccine.
   Google Scholar
• EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca | european Medicines Agency [ Internet]. [ cited 2021 Jan 13]. Available from: https://www.ema.europa.eu/en/news/ema-receives-application-conditional-marketing-authorisation-covid-19-vaccine-astrazeneca.
   Google Scholar
• Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467–478.
   PubMed Web of Science ®Google Scholar
• Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111.
   PubMed Web of Science ®Google Scholar
• Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2020;396(10267):1979–1993.
   Web of Science ®Google Scholar
• Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671–681.
   PubMed Web of Science ®Google Scholar
• AstraZeneca will test using component of Russia’s Sputnik V in clinical trials of its own vaccine against coronavirus | official website vaccine against COVID-19 Sputnik V. [ Internet]. [ cited 2020 Dec 11]. Available from: https://sputnikvaccine.com/newsroom/pressreleases/astrazeneca-will-test-using-component-of-russia-s-sputnik-v-in-clinical-trials-of-its-own-vaccine-ag/.
   Google Scholar
• Sadoff J, Le Gars M, Shukarev G, et al. Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine. N Engl J Med. 2021. NEJMoa2034201. 10.1056/NEJMoa2034201
   Web of Science ®Google Scholar
• World Health Organization. Draft landscape of COVID-19 candidate vaccines [ Internet]. [ cited 2020 Nov 18]. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
   Google Scholar
• Trial will assess safety of potential vaccines when inhaled – UKRI [ Internet]. [ cited 2020 Dec 14]. Available from: https://www.ukri.org/our-work/tackling-the-impact-of-covid-19/vaccines-and-treatments/trial-will-assess-safety-of-potential-vaccines-when-inhaled/.
   Google Scholar
• Qiu Y, Man RCH, Liao Q, et al. Effective mRNA pulmonary delivery by dry powder formulation of PEGylated synthetic KL4 peptide. J Control Release. 2019;314:102–115.
   PubMed Web of Science ®Google Scholar
• Tomar J, Born PA, Frijlink HW, et al. Dry influenza vaccines: towards a stable, effective and convenient alternative to conventional parenteral influenza vaccination. Expert Rev Vaccines. 2016;15(11):1431–1447.
   PubMed Web of Science ®Google Scholar
• Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine programme to improve immune response in the elderly | GSK [ Internet]. [ cited 2021 Jan 14]. Available from: https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-announce-a-delay-in-their-adjuvanted-recombinant-protein-based-covid-19-vaccine-programme-to-improve-immune-response-in-the-elderly/.
   Google Scholar
• Wiley JA, Richert LE, Swain SD, et al. Inducible bronchus-associated lymphoid tissue elicited by a protein cage nanoparticle enhances protection in mice against diverse respiratory viruses. PLoS One. 2009;4(9):e7142.
   PubMed Web of Science ®Google Scholar
• Ma H, Zeng W, He H, et al. Serum IgA, IgM, and IgG responses in COVID-19. Cell Mol Immunol. 2020;17(7):773–775.
   PubMed Web of Science ®Google Scholar
• Hasan Ali O, Bomze D, Risch L, et al. Severe Coronavirus Disease 2019 (COVID-19) is Associated With Elevated Serum Immunoglobulin (Ig) A and Antiphospholipid IgA Antibodies. Clin Infect Dis. 2020. 10.1093/cid/ciaa1496.
   Google Scholar
• Yu H, Sun B, Fang Z, et al. Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients. Eur Respir J. 2020;56(2):2001526.
   PubMed Web of Science ®Google Scholar
• Tang Y, Liu J, Zhang D, et al. Cytokine Storm in COVID-19: the Current Evidence and Treatment Strategies. Front Immunol. 2020;11:1708.
   PubMed Web of Science ®Google Scholar
• Serazin NA, Edem B, Williams SR, et al. Acute respiratory distress syndrome (ARDS) as an adverse event following immunization: case definition & guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2021.
   PubMed Web of Science ®Google Scholar
• Hoppentocht M, Hoste C, Hagedoorn P, et al. In vitro evaluation of the DP-4M PennCenturyTM insufflator. Eur J Pharm Biopharm. 2014;88(1):153–159.
   PubMed Web of Science ®Google Scholar
• Cossío U, Gómez-Vallejo V, Flores M, et al. Preclinical evaluation of aerosol administration systems using Positron Emission Tomography. Eur J Pharm Biopharm. 2018;130:59–65.
   PubMed Web of Science ®Google Scholar
• Lexmond AJ, Keir S, Terakosolphan W, et al. A novel method for studying airway hyperresponsiveness in allergic guinea pigs in vivo using the PreciseInhale system for delivery of dry powder aerosols. Drug Deliv Transl Res. 2018;8(3):760–769.
   PubMed Web of Science ®Google Scholar
• Tonnis WF, Bagerman M, Weij M, et al. A novel aerosol generator for homogenous distribution of powder over the lungs after pulmonary administration to small laboratory animals. Eur J Pharm Biopharm. 2014;88(3):1056–1063.
   PubMed Web of Science ®Google Scholar
• Price DN, Kunda NK, Muttil P. Challenges Associated with the Pulmonary Delivery of Therapeutic Dry Powders for Preclinical Testing. KONA Powder Part J. 2019;36:129–144.
   Google Scholar
• Nikander K, Nicholls C, Denyer J, et al. The Evolution of Spacers and Valved Holding Chambers. J Aerosol Med Pulm Drug Deliv. 2014;27(S1):S-4-S-23.
   Google Scholar
• Sterlin D, Mathian A, Miyara M, et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci Transl Med. 2021;13(577):eabd2223.
   PubMed Web of Science ®Google Scholar
• Wang Z, Lorenzi JCC, Muecksch F, et al. Enhanced SARS-CoV-2 neutralization by dimeric IgA. Sci Transl Med. 2020;eabf1555.
   PubMed Web of Science ®Google Scholar
• Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;80(6529):eabf4063.
   Google Scholar
• Hassan AO, Kafai NM, Dmitriev IP, et al., A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2. Cell. 183(1): 169–184.e13. 2020.
   PubMed Web of Science ®Google Scholar
• Martini V, Paudyal B, Chrun T, et al. Simultaneous Aerosol and Intramuscular Immunization with Influenza Vaccine Induces Powerful Protective Local T Cell and Systemic Antibody Immune Responses in Pigs. J Immunol. 2021;206(3):652–663.
   PubMed Web of Science ®Google Scholar
• Oude Munnink BB, Sikkema RS, Nieuwenhuijse DF, et al. Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans. Science. 2021;371(80):172–177.
   PubMedGoogle Scholar
• Morgan SB, Hemmink JD, Porter E, et al. Aerosol Delivery of a Candidate Universal Influenza Vaccine Reduces Viral Load in Pigs Challenged with Pandemic H1N1 Virus. J Immunol. 2016;196(12):5014–5023.
   PubMed Web of Science ®Google Scholar
• Pabst R. The pig as a model for immunology research. Cell Tissue Res. 2020;380(2):287–304.
   PubMed Web of Science ®Google Scholar
• Kupferschmidt K. Fast-spreading U.K. virus variant raises alarms. Science. 2021;371(80–):9–10.
   PubMedGoogle Scholar
• Tegally H, Wilkinson E, Giovanetti M, et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. MedRxiv.https://doi.org/10.1101/2020.12.21.202468640
   Google Scholar
• Voloch CM, F R Da S, De Almeida LGP, et al. Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil. medRxiv. 2020.
   Google Scholar
• Díaz Ortega JL, Castaneda D, Arellano Quintanilla DM, et al. Antibody persistence in children aged 6–7 years one year following booster immunization with two MMR vaccines applied by aerosol or by injection. Vaccine. 2017;35(23):3116–3122.
   PubMed Web of Science ®Google Scholar
• Díaz-Ortega J-L, Bennett JV, Castañeda-Desales D, et al. Booster immune response in children 6–7 years of age, randomly assigned to four groups with two MMR vaccines applied by aerosol or by injection. Vaccine. 2014;32(29):3680–3686.
   PubMed Web of Science ®Google Scholar
• Diaz-Ortega JL, Bennett JV, Castaneda D, et al. Successful seroresponses to measles and rubella following aerosolized Triviraten vaccine, but poor response to aerosolized mumps (Rubini) component: comparisons with injected MMR. Vaccine. 2010;28(3):692–698.
   PubMed Web of Science ®Google Scholar
• Díaz-Ortega JL, Bennett JV, Castañeda D, et al. Antibody persistence in young adults 1 year after MMR immunization by aerosol or by subcutaneous route. Vaccine. 2010;28(44):7228–7232.
   PubMed Web of Science ®Google Scholar
• Wong-Chew RM, Islas-Romero R, Mdl -G-G, et al. Immunogenicity of aerosol measles vaccine given as the primary measles immunization to nine-month-old Mexican children. Vaccine. 2006;24(5):683–690.
   PubMed Web of Science ®Google Scholar
• Castro JFD, Bennett JV, Rincon HG, et al. Evaluation of immunogenicity and side effects of triple viral vaccine (MMR) in adults, given by two routes: subcutaneous and respiratory (aerosol). Vaccine. 2005;23(8):1079–1084.
   PubMed Web of Science ®Google Scholar
• Wong‐Chew RM, Islas‐Romero R, García‐garcía De L M, et al. Induction of Cellular and Humoral Immunity after Aerosol or Subcutaneous Administration of Edmonston‐Zagreb Measles Vaccine as a Primary Dose to 12‐Month‐Old Children. J Infect Dis. 2004;189(2):254–257.
   PubMed Web of Science ®Google Scholar
• Bellanti JA, Zeligs BJ, Mendez-Inocencio J, et al. Immunologic studies of specific mucosal and systemic immune responses in Mexican school children after booster aerosol or subcutaneous immunization with measles vaccine. Vaccine. 2004;22(9–10):1214–1220.
   PubMed Web of Science ®Google Scholar
• Sepúlveda-Amor J, Valdespino-Gómez JL, García-garcía De L M, et al. A randomized trial demonstrating successful boosting responses following simultaneous aerosols of measles and rubella (MR) vaccines in school age children. Vaccine. 2002;20(21–22):2790–2795.
   PubMed Web of Science ®Google Scholar
• Sabin AB, Arechiga AF, Castro JF, et al. Successful Immunization of Children With and Without Maternal Antibody by Aerosolized Measles Vaccine: i. Different Results With Undiluted Human Diploid Cell and Chick Embryo Fibroblast Vaccines. JAMA J Am Med Assoc. 1983;249:2651–2662.
   PubMed Web of Science ®Google Scholar
• Dilraj A, Cutts FT, Bennett JV, et al. Persistence of measles antibody two years after revaccination by aerosol or subcutaneous routes. Pediatr Infect Dis J. 2000;19(12):1211–1213.
   PubMed Web of Science ®Google Scholar
• Khanum S, Garelick H, Uddin N, et al. Comparison of Edmonston-Zagreb and Schwarz strains of measles vaccine given by aerosol or subcutaneous injection. Lancet. 1987;329(8525):150–153.
   Google Scholar
• Sabin AB, Arechiga AF, Castro JF, et al. Successful Immunization of Infants With and Without Maternal Antibody by Aerosolized Measles Vaccine: II. Vaccine Comparisons and Evidence for Multiple Antibody Response. JAMA J Am Med Assoc. 1984;251:2363–2371.
   PubMed Web of Science ®Google Scholar
• Ganguly R, Durrer B, Waldman RH. Rubella Virus Immunization of Preschool Children via the Respiratory Tract. Am J Dis Child. 1974;128(6):821–823.
   PubMedGoogle Scholar
• Sabin AB. Immunization Against Measles by Aerosol. Clin Infect Dis. 1983;5(3):514–523.
   Google Scholar
• Cutts FT, Clements CJ, Bennett JV. Alternative routes of measles immunization: a review. Biologicals. 1997;25(3):323–338.
   PubMed Web of Science ®Google Scholar
• FDA. Vaccines Licensed for Use in the United States | FDA [Internet]. [cited 2020 Nov 19]. Available from: https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states.
   Google Scholar
• De Boer AH, Hagedoorn P, Westerman EM, et al. Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept (Twincer®) for high powder doses. Eur J Pharm Sci. 2006;28:171–178.
   PubMed Web of Science ®Google Scholar